RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML)

Authors
Publication date
1 January 2014
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Archivio istituzionale della ricerca - Alma Mater Studiorum Università di Bologna

    redirect
    oaioai:cris.unibo.it:11585/628640
    Last time updated on 04/09/2019